Neuroendocrine Carcinoma — Trials

Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,533 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 515
Recruiting: 262
Ph III recruiting: 30
Growth YoY: +2.5%
Industry share: 38%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (213)

clinicaltrialsPublishedShowing 401–450 of 599 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06211036	Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab(DeLLphi-305)	active not recruiting	Phase 3	563	AmgenINDUSTRY	29	Dec 17, 2025	clinicaltrials
NCT07289048	A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression	not yet recruiting	Phase 2	35	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology